🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 852mg
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 155mg
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 130mg

Other Ingredients

Microcrystalline Cellulose Croscarmellose Sodium Stearic Acid Magnesium Stearate Silicon Dioxide

Label Claims — Verification

All Other
All Other (98% of products) Structure/Function (89% of products) Nutrient (76% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions for use: Virt-Phos 250 Neutral should be taken with a full glass of water, with meal and at bedtime. Adults: One or two tablets four times daily; Pediatric patients over 4 years of age: One tablet four times daily; Pediatric under 4 years of age: Use only as directed by a licensed healthcare practitioner.

⚠️ Warnings & Precautions

Allergy: Product may be exposed to tree nuts, peanuts, fish, egg, wheat, milk, soy, and shellfish during manufacture. See prescribing information.

Precautions, contraindications, side effects: See prescribing information.

Keep out of reach of children

Call your licensed medical practitioner about side effects. You may report side effects by calling Vitrus at 1-888-848-3593 or FDA at 1-800-FDA-1088.

🧪 Formulation Notes

Supplying 250 mg per tablet

Each tablet yields approximately 250 mg (25% DV for adults) of phosphorus. 298 mg sodium (13.0 mEq), and 45 mg of potassium (1.1 mEq).

Description: Virt-Phos 250 Neutral is a prescription phosphorus dietary supplement - supplying 250 mg per tablet for use in the dietary supplement of hypophosphatemia and should be administered under the supervision of a licensed medical practitioner.

Additional Information

69543-268-10

Rx Made in USA

Storage: Store at 20(0) to 25(0)C (68(0) to 77(0)F). Excursions permitted to 15(0) to 30(0)C (59(0) to 86(0)F). Protect from light and moisture. Dispense in a tight, light-resistant container. Notice: Contact with moisture may product surface discoloration or erosion.

Rev. 06/16

Product Details

UPC / SKU 3 69543 26810 1
DSLD Entry Date 2018-09-21
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 180560
Data Updated 2026-04-11

Research Evidence

46 Research Sources
55 Avg Quality Score
23 Meta Analysis
7 Systematic Review
7 Rct
4 Clinical Trial
2 Other
1 Guideline
1 Regulatory Source
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2025
B Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Meta Analysis The Cochrane database of systematic reviews 2011
B Calcium and phosphorus supplementation of human milk for preterm infants
Systematic Review The Cochrane database of systematic reviews 2017
B Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
Meta Analysis Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020
B ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
Guideline Clinical nutrition (Edinburgh, Scotland) 2018
B Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Annals of palliative medicine 2022
B Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
Meta Analysis The Cochrane database of systematic reviews 2015
B The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Journal of nephrology 2022
B Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies
Meta Analysis Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024
View all evidence for Phosphorus →

Compare Similar Products

View all Phosphorus products →